(MedPage Today) — CHICAGO — RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer.
The phase III study showed that second-line daraxonrasib, an investigational oral RAS(ON) multi-selective…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
